Navigation Links
Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
Date:8/25/2013

ys of completion of the last therapy.  Approval is based on response rate.  Currently, no data are available for Kyprolis that demonstrate an improvement in progression-free survival or overall survival.

Important Safety Information Regarding Kyprolis® (carfilzomib) for Injection

On July 20, 2012, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Kyprolis® (carfilzomib) for Injection for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval was based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.

Safety data have been evaluated in 526 patients with relapsed and/or refractory multiple myeloma who received single-agent Kyprolis. There were 37 deaths in the phase 2 studies, or 7% of patients. The most common causes of death, other than disease progression, were cardiac (5 patients), end-organ failure (4 patients), and infection (4 patients). Important warnings and precautions include cardiac arrest, congestive heart failure, myocardial ischemia; pulmonary hypertension, pulmonary complications, infusion reactions, tumor lysis syndrome, thrombocytopenia, hepatic toxicity and embryo-fetal toxicity.

Death due to cardiac arrest has occurred within a day of Kyprolis administration. Patients with New York Heart Association Class III and IV heart failure, myocardial infarction in the preceding 6 months, and conduction abnormalities uncontrolled by medications were not eligible for the clinical trials. These patients may be at greater risk for cardiac complications.

Pulmonary arterial hypertension (PAH) was reported in 2% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients. Dyspnea was reported in 35% o
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... According to a new market ... Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... 17,689.0 Million USD by 2020 at a CAGR of ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... SOUTH SAN FRANCISCO, Calif., May 6 Exelixis,Inc. ... for the first quarter,ended March 31, 2008., ... were $27.9 million,compared to $28.1 million for the ... consistent with 2007, but reflect the completion of,revenue ...
... DIEGO, May 6 TriLink BioTechnologies (TriLink), ... has been awarded a,Phase II Small Business ... continue its investigation of modified dNTPs to ... studies demonstrated that TriLink,s,unique dNTP modifications enhanced ...
Cached Medicine Technology:Exelixis Announces First Quarter 2008 Financial Results 2Exelixis Announces First Quarter 2008 Financial Results 3Exelixis Announces First Quarter 2008 Financial Results 4Exelixis Announces First Quarter 2008 Financial Results 5Exelixis Announces First Quarter 2008 Financial Results 6TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project 2
(Date:8/28/2015)... ... August 28, 2015 , ... An article ... pizza maker Paul LaRocco has gone through to open a pizzeria in Westchester. Mr. ... process tends to take several months, but the current process, having already gone on ...
(Date:8/28/2015)... ... ... For Dallas, the time is nearing for the annual Heart Walk, and North ... American Heart Association hosts their well-known Heart Walk to raise money in awareness and ... be made. Walkers can participate in the cause and someone can also donate, even ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug ... of the “Music With A Mission” benefit concert in Mendon, IL. Held in the ... raise money to support music education programs in the underfunded local school districts of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
Breaking Medicine News(10 mins):Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... impact predicted to be mild , TUESDAY, Dec. 8 (HealthDay ... impact of the H1N1 swine flu pandemic during the autumn-winter ... , "As more detailed data have become available, we ... this disease is. Early on, it was difficult to measure ...
... following was released today by Randall Terry, Director, Operation Rescue ... team members will travel to 13 Cathedrals in 9 states ... at the Boston Cathedral, the seat of Cardinal O,Malley, the ... Kerry families. , They will ask Catholic Bishops: "Your ...
... ... MDRX ) Chief Executive Officer Glen Tullman will host a webcast ... to introduce two new innovations: Allscripts Professional(TM) EHR 9.0 ... Record for small- and medium-sized physician groups; and Allscripts Remote ...
... HUNTINGTON BEACH, California and AMSTERDAM, December 8 ,Agendia, ... will be presenting six studies focusing on MammaPrint(R) at the ... conferences in,breast cancer research worldwide. The SABCS will take place ... Antonio, Texas, USA. , Agendia,s studies ...
... , CINCINNATI, Dec. 8 ... leading provider of document workflow solutions for hospitals, today announced ... technology to improve quality and operating efficiency by providing their ... their healthcare enterprise. The implementation of the Company,s enterprise ...
... YORK, Dec. 8 Parenting a family of any size or ... is that in this "second family," the parenting does not involve ... , According to William Bryan, Ph.D., cofounder of Active Seniors ... define this particular phenomenon that affects 10 million households where an ...
Cached Medicine News:Health News:Swine Flu Pandemic May Be Less Severe Than Expected 2Health News:Abortion, Bishops, and Healthcare: Announcing 'Deaf at the Cathedral' Tour in Nine States. 2Health News:Allscripts Launches New Innovations in Live Event 2Health News:Allscripts Launches New Innovations in Live Event 3Health News:Allscripts Launches New Innovations in Live Event 4Health News:Allscripts Launches New Innovations in Live Event 5Health News:Allscripts Launches New Innovations in Live Event 6Health News:Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium 2Health News:Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium 3Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 2Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 3Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 4Health News:'Sandwich Generation' Avoids Unnecessary Stress While Tending to Aging Senior Parents 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: